Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.40 |
| ▸ | AKT2 | P31751 | 4/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 4/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TLK2 | Q86UE8 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | BRD2 | P25440 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4611898 | 1.00 | ROCK2 (0.40) | ROCK2AKT2PDPK1AKT1KMT2A | |
| SCHEMBL14587215 | 1.00 | ROCK2 (0.40) | ROCK2AKT2PDPK1AKT1KMT2A | |
| SCHEMBL7984825 | 0.93 | ROCK2 (0.41) | ROCK2PDPK1TLK2JAK3SLC2A1 | |
| SCHEMBL8186879 | 0.91 | ROCK2 (0.48) | ROCK2SLC2A1GSK3B | |
| SCHEMBL6984569 | 0.91 | JAK3 (0.42) | ROCK2PDPK1KMT2AJAK3SLC2A1 | |
| SCHEMBL6984575 | 0.91 | JAK3 (0.42) | ROCK2PDPK1KMT2AJAK3SLC2A1 | |
| SCHEMBL8186883 | 0.91 | ROCK2 (0.48) | ROCK2SLC2A1GSK3B | |
| SCHEMBL4613544 | 0.91 | NR1H4 (0.39) | ROCK2AKT2PDPK1AKT1KMT2A | |
| SCHEMBL4613550 | 0.91 | NR1H4 (0.39) | ROCK2AKT2PDPK1AKT1KMT2A | |
| SCHEMBL6982535 | 0.90 | ROCK2 (0.43) | ROCK2SLC2A1GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1727798-B1 | NOVEL ARYL-CONTAINING 5-ACYLINDOLINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2008-10-29 | — | — | EP | disclosed |
| US-7176231-B2 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-13 | — | — | US | disclosed |
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234120-A1 | Aryl-containing 5-acylindolinones, the preparation thereof and their use as medicaments | GSK3B, GSK3A, CSNK2A3 | ROCK2 930/4885AKT2 237/4885PDPK1 110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.